Kornimate/medical-research-clean huggingface dataset:
partial neuromuscular blockade for lung protective mechanical ventilation

Conditions: Respiratory Insufficiency

Summary: controlled mechanical ventilation may lead to the development of diaphragm muscle atrophy, which is associated with weakness and adverse clinical outcome. therefore, it seems reasonable to switch to partially supported ventilator modes as soon as possible. however, in patients with high respiratory drive, the application of partially supported modes may result in high lung distending pressures and diaphragm injury. recently, the investigators published a study that demonstrated that a low dose of neuromuscular blocking agents (nmba) facilitates lung-protective ventilation and maintains diaphragm activity in intensive care unit (icu) patients. that study was conducted in a small (n=10), selected group of patients and partial neuromuscular blockade was applied for only 2 hours (proof-of-concept study). therefore, further research has to be done before this strategy can be applied in clinical practice. the primary goal is to investigate the feasibility and safety of prolonged (24 hours) partial neuromuscular blockade in patients with high respiratory drive in partially supported mode. the secondary goals are to evaluate the effect of this strategy diaphragm function, lung injury, hemodynamics and systemic inflammation.


Eligibility criteria:
inclusion criteria: * high respiratory drive, defined as tidal volume \> 8ml/kg pbw on inspiratory support of 12 cmh2o. * sedation level: richmond agitation-sedation scale (rass) ≤ -3 * ventilated in pressure support mode exclusion criteria: * recent use of nmba (\< 2 hrs) * arterial ph \< 7.25 * hemodynamic instability, i.e. high dose vasopressors (\>0.5 μg/kg/min) or inotropes (dobutamine \>15 μg/kg/min or enoximone \>25 μg/kg/min) * intracranial pressure \> 20 cmh2o * past medical history of neuromuscular disorders * known pregnancy * known previous anaphylactic reaction to nmba's.
randomised controlled study of popofol versus midazolam as sedation in endoscopy with advanced liver disease.

Conditions: Liver Diseases

Summary: gastrointestinal endoscopy is a frequent procedure in the patients with advanced liver disease. it requires variable degree of sedation ranging from minimal sedation to general anesthesia aiming for relieving pain, anxiety, and bad memories of the procedure. in conscious sedation, patients are able to make purposeful responses to auditory and tactile clues, with maintenance of ventilatory and circulatory stability. while, in deep sedation, patients respond only to painful stimuli, and airway support is frequently required. at the level of general anesthesia, patients are unresponsive, and airway support is mandatory.

the aim of this study is to compare use of propofol or midazolam as sedative for patients with advanced liver disease presented for gastrointestinal endoscopy.

Eligibility criteria:
inclusion criteria: * patients aged between 40 and 60 years old. * with child score b or c * presented for elective gastrointestinal endoscopy exclusion criteria: * emergent condition like hematemesis. * patients with moderate to severe hepatic encephalopathy. * patients with hepatopulmonary syndrome. * patients with known or suspected hypersensitivity to the used medication were also excluded from the study.
movement visualization in patients with hemophilic arthropathy

Conditions: Hemophilia

Summary: background. the recurrence of hemarthrosis in patients with hemophilia favors the development of an intra-articular, degenerative and progressive lesion (hemophilic arthropathy). pain is one of the main clinical manifestations of this arthropathy. objective. assess the safety and efficacy of an intervention in pain through visualization of the movement using a mobile application of augmented reality and immersive 360º video, regarding the frequency of bleeding and the improvement of pain perception and quality of life, joint state , strength and functionality in patients with hemophilic arthropathy. study design. randomized, multicenter, simple blind clinical study. method. 140 patients with hemophilia a and b will be recruited in this study. patients will be recruited in 5 regions of spain. the 8 dependent variables will be: frequency of bleeding (self-registration), pain (measured with the visual analogue scale and pressure algometer, tampa scale of kinesiophobia and pain catastrophizing scale), quality of life (sf-12 scale), anxiety (questionnaire anxiety state-trait-stai), joint state (hemophilia joint health score scale), muscular strength (dynamometer) and functionality (6-minutes walking test, quick disabilities of the arm, shoulder and hand). three evaluations will be carried out: pre-treatment, post-treatment and after a 6-month follow-up period. expected results. observe the effectiveness of movement visualization in the characteristics of pain, and its implication in functionality, joint state, muscular strength and the perception of quality of life in patients with hemophilic arthropathy.


Eligibility criteria:
inclusion criteria: * patients diagnosed with hemophilia a and b * medical diagnosis of hemophilic arthropathy * chronic joint pain * over 18 years * on prophylactic treatment or on demand with fviii / fix concentrates exclusion criteria: * patients with neurological or cognitive disorders that impede the understanding of the questionnaires * painless patients * amputee, epileptic or seriously impaired vision patients * patients receiving physiotherapy treatment at the time of the study * patients who have not signed the informed consent document.

Keywords: hemophilic arthropathy educative intervention pain quality of life anxiety stress
azd0530 study 21 - phase i study in patients with solid tumours

Conditions: Solid Tumor

Summary: this is a dose escalation study to assess the safety and tolerability of azd0530 in patients with advanced solid malignancies.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed advanced carcinoma / solid tumour of known primary site, which is refractory to standard therapies or for which no standard therapy exists * world health organisation (who) performance status 0 to 2 * life expectancy of at least 12 weeks exclusion criteria: * inadequate bone marrow reserve * inadequate liver function, renal function or low hemoglobin * unresolved toxicity from anti-cancer therapy

Keywords: advanced carcinoma
a phase 1/2 study evaluating amg 337 in asian subjects

Conditions: Stomach Neoplasms

Summary: this is a multicenter, phase 1/2 study. the study will evaluate the tolerability, safety and activity of amg 337 in asian subjects who have advanced solid tumors (phase 1) or subjects with met amplified tumors with a focus on gastric/gastroesophageal junction/esophageal adenocarcinoma (phase 2).

this is a phase 1/2, multicenter, single arm, open-label study to assess the safety, efficacy and pharmacokinetics of amg 337 in solid tumors. in the phase 1, approximately 3 to 45 subjects enrolled in a 3+3+3 dose escalation scheme evaluating two dose levels. in the phase 2, approximately 140 subjects will be enrolled to either cohort 1 (subjects with met amplified /gastroesophageal junction/esophageal (g/gej/e) adenocarcinoma with measurable tumor) or cohort 2 (subjects with met amplified solid tumors with measurable tumor and subjects with met amplified g/gej/e adenocarcinoma with non-measurable tumor). all subjects will self-administer amg 337 daily until disease progression or other protocol specified end of treatment criteria are met. tumor assessment by recist 1.1 will be followed during study treatment. tumor tissue, biomarkers, pharmacokinetics and patient reported outcomes will be assessed.

Eligibility criteria:
inclusion criteria: * able to self administer daily amg 337 as a whole capsule * male or female 20 years of age or over * phase 1: subjects must have a pathologically confirmed, advanced solid tumor for which the subjects have received prior therapy for advanced disease, for which no standard therapy exists, or the subject refuses standard therapy. * phase 2: subjects must have a pathologically confirmed, advanced g/gej/e adenocarcinoma (cohort 1) or other solid tumor (cohort 2) for which the subjects have received prior therapy for advanced disease, or for which no standard therapy exists, or the subject refuses standard therapy. * tumor met amplified by protocol-specified centralized testing (phase 2 only). * phase 1: measurable or non-measurable disease per recist v1.1 * phase 2: measurable disease per recist v1.1 guidelines. cohort 2 may include subjects with advanced met amplified g/gej/e adenocarcinoma with non-measurable tumor per recist v1.1. * (ecog) performance status of 0, 1, or 2 * other protocol defined inclusion criteria may apply. exclusion criteria: * known central nervous system metastases. * subject is a candidate for curative surgery or definitive chemoradiation. * peripheral edema \> grade 1. * subjects who have persistent gastric outlet obstruction, complete dysphagia or are dependent upon jejunostomy for feeding. significant gastrointestinal disorder(s) that in the opinion of the investigator may influence drug absorption. * currently receiving any anti-tumor treatments, or less than 14 days prior to enrollment since ending anti-tumor treatment. * prior treatment with small molecule inhibitors of the met pathway. * other protocol defined exclusion criteria may apply.

Keywords: met amplified gastric/ gastroesophageal junction/ esophageal adenocarcinomas, or other solid tumors
clinical value of sequential gefitinib with pemetrexed/platinum for advanced nsclc

Conditions: NSCLC

Summary: the aim of this study is to explore the clinical value of sequential gefitinib with pemetrexed/platinum compare with pemetrexed/platinum for advanced nsclc.

patients will be randomized to 2 groups

Eligibility criteria:
inclusion criteria: 1. 18\~70 years 2. patients who were diagnosed by the histologic, cytologic diagnosis of iiib-iv non-small cell lung cancer 3. presence of at least one index lesion measurable by ct scan or mri 4. ecog0-1 5. expected life time longer than 12 weeks 6. normal laboratory values: * leucocyte ≥ 4×109/l * neutrophil ≥ 1.5×109/l * platelet ≥ 100×109/l * hemoglobin ≥ 10g/l * alt and * ast ≤ 2.5×uln (≤ 5×uln if liver metastasis) 7. signed written informed consent exclusion criteria: * patients have used drugs according to protocol * patients were allergic to pemetrexed or cisplatin * patients received radiotherapy or other biological treatment 4 weeks before the trial * uncontrolled hydrothorax or hydropericardium * neuropathy toxicity ≥ ctc 3 * severe symptomatic heart disease * active upper gastrointestinal ulcer or digestive disfunction * severe infection or metabolic disfunction * patients with other malignant tumor * uncontrolled brain metastases * patients have accepted other clinical trials * female patients during their pregnant and lactation period, or patients without contraception
sexual dysfunction in patients with myofascial pain syndrome

Conditions: Sexual Dysfunction; Myofascial Pain Syndrome

Summary: this study evaluates the frequency of sexual dysfunction in women with myofascial pain syndrome and its relationship with clinical parameters.

the frequency of sexual dysfunction in reproductive-aged married women with primary myofascial pain syndrome will be evaluated in a prospective, cross-sectional survey-type study. the medical history of each participant was obtained and they underwent a detailed physical examination. sociodemographic and clinic characteristics of all participants (age, education, marital status, employment status, family structure, income status, body mass index(bmi), disease duration, number of pregnancies, sleep quality, etc.) were recorded. pain and fatigue levels of the patients were measured by the visual pain scale (vas), mood states by the beck depression index (bdi), sexual function of the participants was assessed by the 0-10 visual analog scale (vas) to assess the degree of importance of sexuality (the sexuality-importance score). in addition, weekly/monthly sexual intercourse frequency was asked to all participants (patient and control groups). the questionnaires were administered to all participants in a room where they were alone with a female physician, and a suitable environment was provided for the patients to fill out the questionnaire. patients were assured of the confidentiality of their information. only questions that were not understood by the patient were explained without guidance.

Eligibility criteria:
inclusion criteria: * myofascial pain syndrome (\>3 months) was diagnosed in a female. * being between the ages of 18 and 50, married, sexually active, and not menopausal * volunteering to participate in the study, and being able to communicate easily. exclusion criteria: * a history of systemic disease (cardiovascular, pulmonary, hepatic, renal, hematological, etc.) * major psychiatric illness, mental retardation * uncontrollable respiratory system problems * endocrine diseases, neurological diseases * previous hysterectomy or vaginal surgery, a history of sexually transmitted diseases * urinary or anal incontinence * limited motion in the upper or lower extremities * fibromyalgia * inflammatory rheumatic diseases (such as rheumatoid arthritis, ankylosing spondylitis, etc.) * cervical/lumbar radiculopathy or myelopathy * communication problems * pregnancy, lactation * taking estrogen therapy * use antidepressant, anxiolytic, and antiepileptic drugs * chronic alcohol users

Keywords: sexual dysfunction myofascial pain sydrome pain
post-marketing surveillance study with micardisplus® in treatment of morning hypertension (self-monitored by patient)

Conditions: Hypertension

Summary: the purpose of the study was to examine the effect of six- to eight-week treatment with micardisplus® on blood pressure and the effect of patient self-monitoring on blood pressure control. in addition, the post-marketing surveillance study offered the possibility to obtain information about the influence on different laboratory parameters during treatment with micardisplus® from an unselected patient group under office conditions


Eligibility criteria:
inclusion criteria: * age \> 18 years * hypertension exclusion criteria: * age \< 18 years
incidence of esophageal lichen planus in patients with known oral lichen planus

Conditions: Lichen Planus

Summary: the lichen planus is a mucocutaneous disease of unknown etiology with an incidence of 1-2%, that affects in 30-70% of cases either the mucosa of the mouth, or partly in combination with infection of the skin, the oral with his known premalignant potential in up to 2-3% predisposed to the development of an oral squamous cell carcinoma.in rare cases, there is also an manifestation of the lining of the esophagus, which can then be associated with symptomatic strictures of the esophagus. the value of moreover increasingly established endoscopic imaging procedures are investigated as well as data of the natural long-term outcome in esophageal lichen planus infestation especially in view of malignant transformation.

the lichen planus is a mucocutaneous disease of unknown etiology that manifests itself with an incidence of 1-2% in 30-70% of cases either at the mucosa of the mouth, or partly in combination with infection of the skin, the oral with his known premalignant potential in up to 2-3% predisposed to the development of an oral squamous cell carcinoma. in rare cases, there is also an manifestation of the lining of the esophagus, which can then be associated with symptomatic strictures of the esophagus. in addition, four cases have been reported with esophageal squamous cell carcinoma in patients with esophageal lichen planus. the value of moreover increasingly established use of narrow-band imaging (a process for improving the detection of early cancers in the gastrointestinal tract by creating a maximum contrast between outright and altered mucosa, which could have already shown an improved detection rate of early lesions of the esophagus as well as squamous cell carcinoma), or the chromoendoscopy has means for example lugol solution in correlation to the histopathologic findings in lichen planus), has not been investigated to date. also, data of the natural long-term outcome in esophageal lichen planus infestation especially in view of malignant transformation are currently not available.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * known lichen planus of the oral mucosa exclusion criteria: * severe cardiopulmonary disease - asa (american society of anaesthesiology) class \> iii * antisecretory and nonsteroidal anti-inflammatory medication within the last month

Keywords: narrow band imaging chromoendoscopy lugol
stretching and pain sensitivity

Conditions: Stretching

Summary: stretching is frequently used in clinical practice to manage musculoskeletal discomfort and to prevent sports injuries. it is not known if stretching affects pain sensitivity. the purpose of this study is to investigate if a 4 week daily stretching protocol alters pain sensitivity. the investigators hypothesize that stretching reduces pain sensitivity.


Eligibility criteria:
inclusion criteria: * aged between 18 and 40 * in general good health, in the opinion of the investigator, based on medical and physical history. * speaks, reads and writes danish language. exclusion criteria: * regular use of stretching * history of surgery to the lower limb(s) * history of traumatic and overuse injures to the lower limb(s), including but not limited to: tendinopathies, bursitis, muscle injuries, significant ankle sprains, other ligament injuries * hyper mobility syndromes, including but not limited to ehlers-danlos syndrome, generalised hyper mobility syndrome * history of symptoms of autoimmune disorders (e.g., inflammatory bowel disease, multiple sclerosis, lupus, rheumatoid arthritis). * planned surgical procedure during the duration of the study * history, diagnosis, or signs and symptoms of clinically significant neurological disease, including but not limited to: stroke or transient ischemic attack, alzheimer's disease or other types of dementia, clinically significant head trauma within the past year, peripheral neuropathy, epilepsy or seizure, impaired balance * alcohol or drug abuse within the last 5 years * history, diagnosis, signs or symptoms of any clinically significant psychiatric disorder * diabetes * subjects with regional pain syndromes suggestive of lumbar compressions with radiculopathy or at risk of developing radiculopathy. * any other condition, which in the opinion of the investigator, would put the subject at increased safety risk or otherwise make the subject unsuitable for this study.
postural drainage with and without aerobic training on chronic suppurative lung disease

Conditions: Lung Disease Chronic

Summary: this will be a randomized controlled trial patients will be divided into two groups randomly. both groups will receive postural drainage as baseline treatment thrice a week for two weeks. the intervention group will undergo additional aerobic training thrice a week for two weeks as well along with postural drainage. aerobic training will include a 5-step stair-climbing and a 10-step walk during each session. data will be collected before and at the end of two weeks. respiratory rate, pulse oximeter, 10-meter endurance walk test, and pediatric cough questionnaire will be used to collect data pre and post-treatment. data will be analyzed by use of spss version 2010. data will be presented in the form of mean and standard deviation.

chronic suppurative lung disease (csld) is a clinical syndrome in children with respiratory symptoms and signs. children who have bronchiectasis symptoms but non-diagnostic scans are described as having chronic suppurative lung disease (csld). postural drainage improves secretion clearance techniques, it is equally as effective as other airway clearance techniques. this study will focus on the implementation of postural drainage and aerobic training in this disease to find their effect on respiratory rate, oxygen saturation, and endurance.

Eligibility criteria:
inclusion criteria: * age of 5-13 years * medically stable, * patients must have 2 episodes of productive cough, each episode lasting for 4 weeks per year. exclusion criteria: * non-chronic suppurative lung disease related chronic disease * chronic suppurative lung disease-related conditions posing an increased risk to the patient when exercising. children with any msk-disorder or gait abnormalities

Keywords: csld, respiratory rate, endurance, oxygen saturation
changes in leukotrienes during cardiac surgery in patients with chronic obstructive pulmonary disease

Conditions: Lung Dysfunction; Inflammatory Response During Cardiac Surgery

Summary: the hypotheses of this study are that: * production and release of inflammatory substances called leukotrienes are increased during heart surgery with use of a heart-lung machine in humans; * the increase in these leukotrienes levels after heart surgery is higher in patients with bronchitis and/or emphysema than in patients without previous history of lung disease; * levels of leukotrienes are directly correlated with worsening of lung function during and after heart surgery.

in this project, we will test the hypothesis that cys-leukotrienes are released and correlated with the impairment of the lung function after cardiac surgery in patients with copd. if such hypothesis is substantiated in the study, it would allow us to propose the use of leukotriene inhibitors in the peri-operative period to improve pulmonary function and to decrease complications after cardiac surgery in copd patients.

Eligibility criteria:
inclusion criteria: * adult patients schedules to undergo cardiac surgery with use of cpb. exclusion criteria: * inability to provide consent; * previous diagnosis of asthma; * acute pre-operative respiratory failure; * emergency surgery.

Keywords: copd cpb leukotrienes
atherosclerotic lesion proteomics by harvesting angioplasty balloons (alpha).

Conditions: Angina, Stable; Angina, Unstable; Non-ST-Segment Elevation Myocardial Infarction (NSTEMI); ST-segment Elevation Myocardial Infarction (STEMI); Vascular Diseases

Summary: the purpose of the study is to identify proteins, metabolites and signal pathways related directly to symptomatic atherosclerosis and to disease progression. in the study, we use residual material from angioplasty catheter balloons and from vascular surgery plus blood samples. it is the hypothesis that material left on the catheter balloons used for angioplasty can be used for proteomics and metabolomics evaluation that will identify inflammation-associated proteins and signaling pathways directly in the diseased vessel. the tissue samples will be collected after the procedure and blood samples will be collected at the procedure plus after 6-12 months. the tissue and blood samples will be analyzed using mass spectrometry methods and a standard panel of biomarkers will also be analyzed using standardized methods. the analyses will include study of inflammation-associated peptides observed in autoinflammation as well as thrombogenic signaling pathways and local expression of biomarkers. the analyses of proteins, metabolites and/or biomarkers will be compared between cases (stable angina, unstable angina/non-stemi, stemi and vascular surgery) and controls (procedures not related to coronary artery diseases) to identify molecular processes related directly to symptomatic atherosclerosis and will be associated with disease progression using data from medical journals and national health registries. the study will recruit 225 patients from rigshospitalet university hospital, copenhagen, and herlev-gentofte hospital.


Eligibility criteria:
inclusion criteria: * symptomatic atherosclerotic disease * 18 years or older * angioplasty or vascular surgery exclusion criteria: - not willing or unable to give informed consent

Keywords: proteomics metabolomics atherosclerosis angioplasty vascular surgery